- Home
- / Mallinckrodt Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Mallinckrodt Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$1 B
FY, 2022
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 3.2B | 2.2B | 2.2B | 1.0B |
| Cost of goods sold | 892.3M | 790.0M | 658.8M | 641.3M | 643.5M |
| Gross profit | 2.4B | 2.9B | 1.6B | 1.6B | 396.2M |
| Gross profit margin, % | 73.2% | 91.8% | 72.9% | 71.0% | 38.1% |
| Operating expense total | 1.3B | 2.9B | 1.3B | 939.7M | 365.4M |
| Depreciation and amortization | 4.7B | 1.3B | 948.7M | 675.8M | 347.5M |
| EBITDA | 1.1B | 47.1M | 297.1M | 627.8M | 30.8M |
| EBITDA margin, % | 32.8% | 1.5% | 13.4% | 28.4% | 3.0% |
| EBIT | (3.7B) | (1.3B) | (705.6M) | (454.2M) | (329.9M) |
| EBIT margin, % | -114.8% | -40.9% | -31.9% | -20.6% | -31.7% |
| Interest income | 8.2M | 9.5M | 5.9M | 1.9M | 3.9M |
| Interest expense | 370.2M | 309.0M | 261.1M | 222.6M | 324.3M |
| Pre tax profit | (4.1B) | (1.6B) | (960.8M) | (829.8M) | (650.3M) |
| Income tax expense | (430.1M) | (584.3M) | 8.9M | (106.3M) | (52.0M) |
| Net Income | (3.6B) | (1.0B) | (969.7M) | (723.5M) | (598.3M) |